Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The licensed U.S
Zhou J, Ling J, Song H, Lv B, Wang L, Shang J
GLP-1 Bridge for Medicare Beneficiaries CMS announced that they will administer the Medicare GLP-1 Bridge using Section 402 authority, which will allow them to provide a short-term program where Medicare beneficiaries can receive FDA-approved GLP-1 obesity medications
They underscore not only the clinical impact of this drug class but also the urgent need to comprehensively review the evolving evidence base, clarify mechanistic insights, and explore future directions in both metabolic and non-metabolic disease contexts
The other direction cagrilintides is to add an entirely different hormonal axis, amylin, alongside the incretin drugs the field already has
When access to potentially life-changing treatment is determined by ability to pay rather than medical need, the divide between who gets healthier and who does not only grows wider.
